1. Home
  2. MGNX vs IGMS Comparison

MGNX vs IGMS Comparison

Compare MGNX & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNX
  • IGMS
  • Stock Information
  • Founded
  • MGNX 2000
  • IGMS 1993
  • Country
  • MGNX United States
  • IGMS United States
  • Employees
  • MGNX N/A
  • IGMS N/A
  • Industry
  • MGNX Biotechnology: Pharmaceutical Preparations
  • IGMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MGNX Health Care
  • IGMS Health Care
  • Exchange
  • MGNX Nasdaq
  • IGMS Nasdaq
  • Market Cap
  • MGNX 87.7M
  • IGMS 82.1M
  • IPO Year
  • MGNX 2013
  • IGMS 2019
  • Fundamental
  • Price
  • MGNX $1.25
  • IGMS $1.31
  • Analyst Decision
  • MGNX Hold
  • IGMS Hold
  • Analyst Count
  • MGNX 9
  • IGMS 8
  • Target Price
  • MGNX $5.33
  • IGMS $6.00
  • AVG Volume (30 Days)
  • MGNX 2.6M
  • IGMS 897.9K
  • Earning Date
  • MGNX 08-05-2025
  • IGMS 08-13-2025
  • Dividend Yield
  • MGNX N/A
  • IGMS N/A
  • EPS Growth
  • MGNX N/A
  • IGMS N/A
  • EPS
  • MGNX N/A
  • IGMS N/A
  • Revenue
  • MGNX $154,050,000.00
  • IGMS $2,681,000.00
  • Revenue This Year
  • MGNX N/A
  • IGMS $134.30
  • Revenue Next Year
  • MGNX N/A
  • IGMS $22.37
  • P/E Ratio
  • MGNX N/A
  • IGMS N/A
  • Revenue Growth
  • MGNX 255.31
  • IGMS 27.36
  • 52 Week Low
  • MGNX $0.99
  • IGMS $0.92
  • 52 Week High
  • MGNX $5.77
  • IGMS $22.50
  • Technical
  • Relative Strength Index (RSI)
  • MGNX 37.88
  • IGMS 57.18
  • Support Level
  • MGNX $1.19
  • IGMS $1.12
  • Resistance Level
  • MGNX $1.41
  • IGMS $1.26
  • Average True Range (ATR)
  • MGNX 0.12
  • IGMS 0.08
  • MACD
  • MGNX -0.03
  • IGMS 0.00
  • Stochastic Oscillator
  • MGNX 4.85
  • IGMS 86.54

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About IGMS IGM Biosciences Inc.

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Share on Social Networks: